Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

Development Leadership Team in Place to Advance Voreloxin to Late-Stage

Trials Strategic Realignment Includes Workforce Reduction to Streamline Operations

SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a corporate realignment to focus on the development of the company's lead oncology product candidate, voreloxin (formerly SNS-595). In conjunction with this strategic restructuring, Sunesis expanded the company's late-stage development leadership team and announced a workforce reduction of approximately 60 percent, including the winding down of its research activities. These changes are intended to concentrate the company's financial and human resources on the strongest path to potential near-term value creation for the company's stockholders.

"Based on the promising clinical data achieved to date, we have made a strategic decision to focus the organization on generating critical clinical data by advancing our lead compound, voreloxin, into late-stage trials in the acute myeloid leukemia and ovarian cancer indications," said Daniel Swisher, Sunesis' Chief Executive Officer. "Late-stage development requires increased focus of our resources. We are also expanding and strengthening our development team with the additions of Drs. Steve Ketchum and Mary Bolton. Their extensive product development and regulatory expertise and track records of successful FDA submissions in a breadth of therapeutic areas will support our plan to advance voreloxin through late-stage trials."

Steven B. Ketchum, Ph.D., has been appointed as Senior Vice President, Research and Development and Mary G. Bolton, M.D., Ph.D., as Vice President,
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2009)..., MEMPHIS, Tenn., Jan. 7 /PRNewswire-USNewswire...e that predict a high likelihood of relapse in chi...hough the researchers caution that further researc...called IKZF1 or IKAROS, lead to leukemia relap...or future diagnostic tests to assess the risk of t...
(Date:1/7/2009)..., OXFORD, England, January 7 /PRNewswire/ -...mpany focused on allergy and critical care, today,...lts achieved in 2008 with,its ToleroMune(R) anti-...,patient recruitment for a further phase II clinic...rway in Canada, has recruited 120 patients with co...
(Date:1/6/2009)..., ROCKVILLE, Md., Jan. 6 /PRNewswire-USNewswire...tical company focused on diseases of epidemic pote...andidate for the treatment of tuberculosis (TB), w...ly awarded clinical program contract to Dynport Va... contract, awarded by the National Institute of Al...
(Date:1/5/2009)..., BETHESDA, Md., Jan. 5 /PRNewswire-FirstCa...rmaceutical company developing novel, proprietary,...ion and autoimmune diseases,provides an outlook ..., Micromet intends to provide an update on its...ng events: , -- April 12 to 16, 2009: Updat...
Breaking Medicine Technology:Gene Abnormality Found to Predict Childhood Leukemia Relapse 2Gene Abnormality Found to Predict Childhood Leukemia Relapse 3Gene Abnormality Found to Predict Childhood Leukemia Relapse 4Gene Abnormality Found to Predict Childhood Leukemia Relapse 5Gene Abnormality Found to Predict Childhood Leukemia Relapse 6Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 2Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Childhood Obesity May Be Leveling Off 20322 1Childhood Obesity May Be Leveling Off 20322 2Childhood Obesity May Be Leveling Off 20322 31 small step for a lab science 1 green leap for mankind 20320 11 small step for a lab science 1 green leap for mankind 20320 2Berkeley Premium Nutraceuticals Pushes Forward 20318 1Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans 20316 1Ohio Association of Health Plans Names Pinnacle Awards to Programs That Improve Health Care for Ohioans 20316 2
...cal data on leading,drug-eluting stent portfolio, ... -- Boston,Scientific Corporation today announced ...ss announcements at the annual Paris,Course on Rev... 22,to 25 in Barcelona, Spain. , "We will be annou... and registries, adding to the knowledge base for ...
...y 15, 2007 - Synthetic Blood,International, Inc. (...tatistical analysis of its Phase IIa study with Ox... In line with preliminary,study results announced ...at the primary endpoint of increasing patients, ox.... Data also show a,decrease in patient glucose and...
Other Medicine Technology:Boston Scientific Announces Schedule for EuroPcr 2007 2Boston Scientific Announces Schedule for EuroPcr 2007 3Boston Scientific Announces Schedule for EuroPcr 2007 4Boston Scientific Announces Schedule for EuroPcr 2007 5Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3
(Date:1/8/2009)...RNewswire/ -- New York City Mayor Michael R. Bloom...on Day" and presented a proclamation to Ilchi Lee,... Association) and developer of Brain Education, a ...nce health, well-being, and mental ability for all... regarding the power of individuals to change them...
(Date:1/8/2009)...n. 8 Today, the Nationa...ith several national leadership organizations issu...of hospice care and protection of the Medicare Hos...in sharing this unified message about end-of-life ...alliative Medicine, Hospice and Palliative Nurses ...
(Date:1/8/2009)...tting on the surface of cancer cells are keys to t...ting and stopping the spread of certain types of c...breast, ovarian and lung, among others. Armed wit...ay for Cancer Research, an Illinois-based philanth...M.D., Ph.D., and her co-workers at the Moores Canc...
(Date:1/8/2009)...atal Solution Key Factor in Decision for Florida M...Fla., Jan. 8 Allscripts ... of the largest multi-specialty group practices in...scripts Enterprise(TM) Electronic Health Record (E... 18 offices across Central Florida. , , (Logo...
Breaking Medicine News(10 mins):Health News:NYC Mayor Michael R. Bloomberg Declares January 8th 'IBREA Brain Education Day' 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4
...e British Medical Journal has noted that there has...ight individuals in China.//China now accounts for...tion. Factors like changes in food habits, change...tivity have been attributed to being responsible f...
...euk Nursery Centre in Wishaw is recovering at home... of the E.coli O157 infection. The Craigneuk Nur...ther cases have been reported. A NHS Lanarkshire...al the child's age or sex, said all staff and pare...
...llah Khan is grateful to Prime Minister Manmohan S...or his treatment//, but is pained that the central...cooking gas agency for one of his grandsons. The ...Bharat Ratna - India's highest civilian honour - i...
...Walsall, was wrongly diagnosed with stomach cancer...ved. Much later, it was found out that the hospita...had only a benign tumor. The operation was carried...Hospital. The pathologist responsible for this mis...
Other Medicine News:Health News:Bismillah Khan frets over government ignoring request 2
...he first objective measurement for CHF. Blood test...diac hormone produced by the heart ventricles in r...re overload. Excellent hormonal marker of ventricu... BNP Test provides meaningful diagnostic informati...
...alvage System offers five different products for l...ese components are cobalt-chrome, ultra high molec...AN products are extensions of Wright Medical Techn... , ,The distal femur consists of a rotating hinge ...
The MOST Options System is designed to enable patients facing severe bone loss of the knee or hip to regain use of their limbs and provides the potential for restoration of function. , ,The system go
...System (OSS) from Biomet Inc. offers the most comp... specifically for orthopaedic surgeons and oncolog...ir patients: significant bone loss, ligamentous de...throplasties, and multiple hip revision arthroplas...
Medicine Products: